Comment: A devastating setback for MND research: Why NICE needs to reconsider its approach to tofersen
Professor Dame Pamela Shaw, Director of the 91Ö±²¥ Institute for Translational Neuroscience, discusses NICE's refusal to classify the MND drug tofersen, as a treatment for a highly specialised condition, rather than just a standard drug.